Tuesday, December 22, 2020 3:34:28 PM
Recent CRIS News
- Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 04/05/2024 11:30:00 AM
- Curis to Present at Upcoming Healthcare Conferences in April • PR Newswire (US) • 04/04/2024 11:30:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:16:14 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/08/2024 09:36:50 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/08/2024 09:27:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/08/2024 09:01:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 01:01:02 PM
- Curis Provides Fourth Quarter 2023 Business Update • PR Newswire (US) • 02/08/2024 01:00:00 PM
- Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 • PR Newswire (US) • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 01:13:35 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 12/21/2023 09:00:47 PM
- Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study • PR Newswire (US) • 12/12/2023 01:00:00 PM
- Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Curis Announces Three Presentations at ASH • PR Newswire (US) • 12/06/2023 01:00:00 PM
- Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma • PR Newswire (US) • 12/05/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/02/2023 12:03:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 12:01:51 PM
- Curis Provides Third Quarter 2023 Business Update • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 • PR Newswire (US) • 10/26/2023 12:30:00 PM
- Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 10/06/2023 12:56:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/28/2023 08:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/28/2023 12:54:37 PM
- Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer • PR Newswire (US) • 09/12/2023 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM